Ten Bridge Communications

Congratulations to #TBCPartner Verona Pharma! Yesterday’s FDA approval of their drug for the maintenance treatment of #COPD marks a significant advance for patients as the first inhaled product with a novel mechanism of action in more than two decades – a game-changing advancement in the standard of care. https://lnkd.in/e9d4s8GH

#TBCPartner X4 Pharmaceuticals' momentum continues with the announcement of interim data from its ongoing Phase 2 trial of mavorixafor, the company’s oral CXCR4 antagonist, in chronic neutropenia. Chronic neutropenia is a rare condition in which patients’ low levels of neutrophils in the blood lead to higher risk of developing infections and reduced quality of life. It’s exciting to see progress toward a new treatment option for these patients.

#TBCPartner Intellia Therapeutics, Inc. continues to push the boundaries of #CRISPR genome editing. While the goal of their therapies in development is to be one-and-done, new data suggest that the editing technology can potentially be redosed, which may have advantages in certain contexts.

It was a privilege to work alongside #TBCPartner HC Bioscience, Inc. on their new brand and website. A leader in #tRNA-based therapies, they are pioneering a new approach in protein editing, with programs in #hemophilia and #DMD. Their new site dives into the science behind tRNA, their platform for treating genetic diseases, and their lead programs.   Give the new site a look.

We want to extend our congratulations to #TBCPartner Sarepta Therapeutics and the entire Duchenne community on last night’s monumental FDA decision. With the expanded label, Sarepta’s gene therapy is now approved for the majority of patients with Duchenne muscular dystrophy.

We are thrilled to welcome Jesena Kalabokis to team TBC via Project Onramp! Jesena joins us from the University of Massachusetts Amherst where she is currently majoring in journalism with a minor in environmental science. In her free time at UMass, she manages a radio station where she plays a different genre of music every week.   Welcome, Jesena – we’re looking forward to an exciting and engaging summer!  

Last week #TBCPartner X4 Pharmaceuticals' Founder, CEO & President Paula Ragan, Ph.D., was joined by BiotechTV's Brad Loncar in X4’s vibrant Boston HQ for a discussion on the company's newly FDA approved treatment for an ultra-rare disease and what's on the horizon.

Congrats to #TBCPartner Rapport Therapeutics on their $154M IPO. We can’t wait to see how their RAP-based platform leads to new possibilities in addressing CNS disease.

Another important milestone for #TBCPartner Intellia Therapeutics, Inc., who announced positive long-term data from its in vivo Phase 1 study of NTLA-2002 for hereditary angioedema (HAE). NTLA-2002 continues to show durable reduction of monthly attack rates with just a single dose, and potential to be a functional cure for people living with this rare disease. Fantastic progress for in vivo gene editing, the field of genomic medicine and #CRISPR technology!

Last week was an exciting one for TBC. Not only did we have some warm, sunny weather, we had nearly all our team members in Boston for our quarterly week of in-person team building and collaboration.   We put our engineering minds to the test, seeing who could build the tallest structure using tape, spaghetti and a marshmallow top. Our winners came in at a towering 21 inches. It also proved that the bridge building we do here at TBC will remain strictly metaphorical.   We also kicked off the summer early with an outing at Cisco Brewers in the Seaport, where we enjoyed some local brews and lawn games.   Thank you to our amazing team members both local and remote for making the trip! Alexis Stefano Rachel S. Leslie (Priest) Humbel Christine Mackenzie